Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 2
2010 4
2011 2
2012 1
2013 1
2015 1
2016 4
2018 2
2020 3
2021 4
2023 4
2024 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM; ENESTnd Investigators. Saglio G, et al. N Engl J Med. 2010 Jun 17;362(24):2251-9. doi: 10.1056/NEJMoa0912614. Epub 2010 Jun 5. N Engl J Med. 2010. PMID: 20525993 Free article. Clinical Trial.
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.
Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, Moiraghi B, Shen Z, Mayer J, Pasquini R, Nakamae H, Huguet F, Boqué C, Chuah C, Bleickardt E, Bradley-Garelik MB, Zhu C, Szatrowski T, Shapiro D, Baccarani M. Kantarjian H, et al. Among authors: moiraghi b. N Engl J Med. 2010 Jun 17;362(24):2260-70. doi: 10.1056/NEJMoa1002315. Epub 2010 Jun 5. N Engl J Med. 2010. PMID: 20525995 Free article. Clinical Trial.
Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial.
Cortes J, Apperley J, Lomaia E, Moiraghi B, Undurraga Sutton M, Pavlovsky C, Chuah C, Sacha T, Lipton JH, Schiffer CA, McCloskey J, Hochhaus A, Rousselot P, Rosti G, de Lavallade H, Turkina A, Rojas C, Arthur CK, Maness L, Talpaz M, Mauro M, Hall T, Lu V, Srivastava S, Deininger M. Cortes J, et al. Among authors: moiraghi b. Blood. 2021 Nov 25;138(21):2042-2050. doi: 10.1182/blood.2021012082. Blood. 2021. PMID: 34407543 Free PMC article. Clinical Trial.
Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study.
Kiladjian JJ, Zachee P, Hino M, Pane F, Masszi T, Harrison CN, Mesa R, Miller CB, Passamonti F, Durrant S, Griesshammer M, Kirito K, Besses C, Moiraghi B, Rumi E, Rosti V, Blau IW, Francillard N, Dong T, Wroclawska M, Vannucchi AM, Verstovsek S. Kiladjian JJ, et al. Among authors: moiraghi b. Lancet Haematol. 2020 Mar;7(3):e226-e237. doi: 10.1016/S2352-3026(19)30207-8. Epub 2020 Jan 23. Lancet Haematol. 2020. PMID: 31982039 Free PMC article. Clinical Trial.
In-depth characterization of NK cell markers from CML patients who discontinued tyrosine kinase inhibitor therapy.
Sanchez MB, Vasconcelos Cordoba B, Pavlovsky C, Moiraghi B, Varela A, Custidiano R, Fernandez I, Freitas MJ, Ventriglia MV, Bendek G, Mariano R, Mela Osorio MJ, Pavlovsky MA, García de Labanca A, Foncuberta C, Giere I, Vera M, Juni M, Mordoh J, Sanchez Avalos JC, Levy EM, Bianchini M. Sanchez MB, et al. Among authors: moiraghi b. Front Immunol. 2023 Sep 25;14:1241600. doi: 10.3389/fimmu.2023.1241600. eCollection 2023. Front Immunol. 2023. PMID: 37818372 Free PMC article. Clinical Trial.
High cell-free DNA is associated with disease progression, inflammasome activation and elevated levels of inflammasome-related cytokine IL-18 in patients with myelofibrosis.
De Luca G, Lev PR, Camacho MF, Goette NP, Sackmann F, Castro Ríos MA, Moiraghi B, Cortes Guerrieri V, Bendek G, Carricondo E, Enrico A, Vallejo V, Varela A, Khoury M, Gutierrez M, Larripa IB, Marta RF, Glembotsky AC, Heller PG. De Luca G, et al. Among authors: moiraghi b. Front Immunol. 2023 Nov 16;14:1161832. doi: 10.3389/fimmu.2023.1161832. eCollection 2023. Front Immunol. 2023. PMID: 38035089 Free PMC article.
Long-Term Follow-Up in Patients With Chronic Myeloid Leukemia Treated With Ponatinib in a Real-World Cohort: Safety and Efficacy Analysis.
Mela Osorio MJ, Moiraghi B, Osycka MV, Pavlovsky MA, Varela AI, Bendek Del Prete GE, Tosin MF, Pérez MA, Riva ME, Berrios RR, Fernández I, Sackmann Massa F, Giere I, Sighel C, Pavlovsky C. Mela Osorio MJ, et al. Among authors: moiraghi b. Clin Lymphoma Myeloma Leuk. 2024 Mar;24(3):158-164. doi: 10.1016/j.clml.2023.10.008. Epub 2023 Oct 26. Clin Lymphoma Myeloma Leuk. 2024. PMID: 37973457
Elevated levels of damage-associated molecular patterns HMGB1 and S100A8/A9 coupled with toll-like receptor-triggered monocyte activation are associated with inflammation in patients with myelofibrosis.
De Luca G, Goette NP, Lev PR, Baroni Pietto MC, Marin Oyarzún CP, Castro Ríos MA, Moiraghi B, Sackmann F, Kamiya LJ, Verri V, Caula V, Fernandez V, Vicente A, Pose Cabarcos J, Caruso V, Camacho MF, Larripa IB, Khoury M, Marta RF, Glembotsky AC, Heller PG. De Luca G, et al. Among authors: moiraghi b. Front Immunol. 2024 Sep 25;15:1365015. doi: 10.3389/fimmu.2024.1365015. eCollection 2024. Front Immunol. 2024. PMID: 39391311 Free PMC article.
COVID-19 in chronic myeloid leukemia patients in Latin America.
Pagnano KB, Peralta EH, Navarro JR, David Salas LDR, Delgado N, Moiraghi B, Toreli ACM, Perobelli LM, Fechio L, Quixada ATS, Funke V, Bendit I, Seguro FS, Pilleux L, Bortolini J, Lourenço ALG, Sapelli J, Nucci FM, Pavlovsky C, Oliveira LDC, Moura MS, Palma LC, Gonçalves NN, Conchon M, Hokama POM, Almeida LL, Zulli R, de Souza CA, Boquimpani CM. Pagnano KB, et al. Among authors: moiraghi b. Leuk Lymphoma. 2021 Dec;62(13):3212-3218. doi: 10.1080/10428194.2021.1950709. Epub 2021 Jul 13. Leuk Lymphoma. 2021. PMID: 34254886
Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal.
Pavlovsky C, Vasconcelos Cordoba B, Sanchez MB, Moiraghi B, Varela A, Custidiano R, Fernandez I, Freitas MJ, Ventriglia MV, Bendek G, Mariano R, Mela Osorio MJ, Pavlovsky MA, de Labanca AG, Foncuberta C, Giere I, Vera M, Juni M, Mordoh J, Sanchez Avalos JC, Cueto G, Miranda S, Levy EM, Bianchini M. Pavlovsky C, et al. Among authors: moiraghi b. J Hematol Oncol. 2023 Apr 29;16(1):43. doi: 10.1186/s13045-023-01440-6. J Hematol Oncol. 2023. PMID: 37120577 Free PMC article.
28 results